Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel

Metabolism: Clinical and Experimental

Volumn 54, Issue 10, 2005, Pages 1276-1281

  Cendros, Joseph M ^a   Peraire, Concepción ^a   Fernández Trocóniz, Iñaki ^b   Obach, Rossend ^a  

^a IPSEN   (France)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; AUTOGEL; GROWTH HORMONE;

ACROMEGALY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; GEL; GROWTH HORMONE BLOOD LEVEL; HORMONE INHIBITION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; TIME SERIES ANALYSIS; TITRIMETRY;

ACROMEGALY; CHEMISTRY, PHARMACEUTICAL; FEMALE; GELS; HUMAN GROWTH HORMONE; HUMANS; MALE; MODELS, BIOLOGICAL; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 24344455912     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2005.04.014     Document Type: Article

References (13)

1. S. Melmed, F.F. Casanueva, F. Cavagnini, P. Chanson, L. Frohman, and A. Grossman Guidelines for acromegaly management J Clin Endocrinol Metab 87 2002 4054 4058
2. M.S. Racine, and A.L. Barkan Medical management of growth hormone-secreting pituitary adenomas Pituitary 5 2002 67 76
3. S. Cannavò, S. Squadrito, L. Curtò, B. Almoto, A. Vieni, and F. Trimarchi Results of a two-year treatment with slow release lanreotide in acromegaly Horm Metab Res 32 2000 224 229
4. P. Caron, I. Morange-Ramos, M. Cogne, and P. Jacquet Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide J Clin Endocrinol Metab 82 1997 18 22
5. R. Baldelli, A. Colao, P. Razzore, M.L. Jaffrain-Rea, P. Marzullo, and E. Ciccarelli Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg) J Clin Endocrinol Metab 85 2000 4099 4103
6. M. Giusti, G. Gussoni, C.M. Cuttica, and G. Giordana Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group J Clin Endocrinol Metab 81 1996 2089 2097
7. S. Lightman Somatuline Autogel: an extended release lanreotide formulation Hosp Med 63 2002 162 165
8. P. Caron, A. Beckers, D.R. Cullen, M.I. Goth, B. Gutt, and P. Laurberg Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly J Clin Endocrinol Metab 87 2002 99 104
9. P. Caron, M. Bex, D.R. Cullen, U. Feldt-Rasmussen, A.M. Pico Alfonso, and S. Pynka One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel Clin Endocrinol 60 2004 734 740
10. M. Barbanoj, R. Antonijoan, A. Morte, J.M. Grinyo, R. Sola, and J. Valles Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency Clin Pharmacol Ther 66 1999 485 491
11. S.L. Beal L.B.S. Sheiner NONMEM user guide-part V. NONMEM project group 1992 University of California at San Francisco Calif (USA) 139
12. E. Comets, F. Mentré, P. Grass, R. Kawai, P. Marbach, and J. Vonderscher Population pharmacodynamic analysis of octreotide in acromegalic patients Clin Pharmacol Ther 73 2003 95 106
13. H. Zhou, T.-L. Chen, M. Marino, H. Lau, T. Miller, and G. Kalafsky Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects Br J Clin Pharmacol 50 2000 543 552